SCHEMBL26425877

SCHEMBL26425877

O=C1NC(=O)/C(=C/c2csc3ncccc23)S1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTR P02766 2/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ AKR1B1 P15121 1/20 0.52
▸ KMT2A Q03164 1/20 0.52
▸ CISD1 Q9NZ45 4/20 0.51
▸ GSK3B P49841 5/20 0.49
▸ PIM1 P11309 3/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ PIK3CA P42336 3/20 0.48
▸ PIK3CG P48736 3/20 0.48
▸ PIK3CD O00329 2/20 0.48
▸ CSNK2A2 P19784 2/20 0.48
▸ PIK3CB P42338 2/20 0.48
▸ MTOR P42345 2/20 0.48
▸ CLK1 P49759 2/20 0.48
▸ DYRK1A Q13627 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ MAOB P27338 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ CSNK2B P67870 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23579374 0.78 PIM1 (0.75) TTRMEN1AKR1B1KMT2AGSK3B
SCHEMBL23579371 0.78 PIM1 (0.75) TTRMEN1AKR1B1KMT2AGSK3B
SCHEMBL23578825 0.76 CHEK1 (0.56) TTRMEN1AKR1B1KMT2ACISD1
SCHEMBL23578828 0.76 CHEK1 (0.56) TTRMEN1AKR1B1KMT2ACISD1
SCHEMBL1249102 0.73 CISD1 (0.71) TTRMEN1AKR1B1KMT2ACISD1
SCHEMBL1250371 0.73 CISD1 (0.64) TTRMEN1AKR1B1KMT2ACISD1
SCHEMBL1250373 0.73 CISD1 (0.64) TTRMEN1AKR1B1KMT2ACISD1
SCHEMBL1249100 0.73 CISD1 (0.71) TTRMEN1AKR1B1KMT2ACISD1
SCHEMBL20954496 0.72 CYP2A6 (0.52) MEN1KMT2ANPC1RAB9A
SCHEMBL29764812 0.71 CISD1 (0.57) TTRMEN1AKR1B1KMT2ACISD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 — — US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP TTR 7/4885MEN1 2152/4885AKR1B1 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback